Extensive DNA Sequencing in Cyclic Vomiting and Chronic Fatigue: Implication for Genetic Testing and Personalized Treatment Options

March 12, 2025 • 01:32:19
Extensive DNA Sequencing in Cyclic Vomiting and Chronic Fatigue: Implication for Genetic Testing and Personalized Treatment Options
MitoAction Expert Series
Extensive DNA Sequencing in Cyclic Vomiting and Chronic Fatigue: Implication for Genetic Testing and Personalized Treatment Options

Mar 12 2025 | 01:32:19

/

Show Notes

In May 2023, Dr. Boles and his research group published a scientific paper on the results of 50 people that had either whole exome or whole genome sequencing. About 30 genes were identified that are highly likely or likely to be risk factors for Cyclic Vomiting Syndrome. The vast majority of these genes involved cation  (kat·ai.aan) (positively-charge salts) channels or mitochondria (energy metabolism), suggesting that disease results from a vicious cycle of cellular over-excitation(x-cytation). Dr. Boles will discuss how genetic information can help find an individual’s genetic predisposition towards cyclic vomiting, and how that translates to treatment options, including those treatments generally not considered in CVS. Lastly, he will briefly discuss 18 chronic fatigue patients with extensive DNA sequencing.

Other Episodes

Episode 0

June 05, 2020 • 01:23:47
Episode Cover

Can People with Mitochondrial Disease Exercise? - Margaret Klehm - 1/4/08

Is Exercise a New Year’s Resolution for People Affected by Mitochondrial Diseases?  Learn about how you can most effectively incorporate exercise into your daily...

Listen

Episode

September 14, 2026 • 01:06:32
Episode Cover

NARP: Understanding the Spectrum of Disease

NARP (Neuropathy, Ataxia, and Retinitis Pigmentosa) is a mitochondrialdisorder with a broad and variable clinical spectrum that can affect the nervous system, vision, movement,...

Listen

Episode

January 28, 2026 • 00:39:28
Episode Cover

Understanding TK2d and the KYGEVVI Approval

Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and...

Listen